FLINDR THERAPEUTICS
LIVE

Serial Number

98451969

Owner

Immagene B.V.

Attorney

Erica R. Halstead

Filing Date

Mar 15, 2024

Add to watchlist:

No watchlists yet
View on USPTO

FLINDR THERAPEUTICS Trademark

Serial Number: 98451969 • Registration: 7798473

FLINDR THERAPEUTICS is a trademark filed by Immagene B.V. on March 15, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Immagene B.V.

Kloosterstraat 9
Amsterdam 5349ABOS , NL

Entity Type: 99

Trademark Details

Filing Date

March 15, 2024

Registration Date

May 20, 2025

Published for Opposition

April 1, 2025

Goods & Services

Pharmaceuticals, medical and veterinary preparations for use in oncology; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for human beings and animals; dietary supplements; pharmaceuticals for use in oncology

Chemicals for use in biotechnological product development; chemicals for use in biotechnological manufacturing processes; chemical preparations, namely, biologically compatible chemical substances for scientific, laboratory, clinical and medical research; biological tissue, namely, mammalian soft and hard tissues comprising or derived from stem cells or progenitor cells for scientific, laboratory, clinical and medical research; therapeutic tissue, namely, therapeutic tissue comprising or derived from stem cells or progenitor cells, and compositions comprising or derived from the therapeutic tissues for scientific, laboratory, clinical and medical research

Pharmaceutical drug discovery and development services; scientific services and research, development and design relating thereto in the field of oncology; medical research; technological services, research and design relating thereto in the fields of small molecule therapeutics; design and development of medical technology; design and development of medical diagnostic apparatus; consultancy services in the field of technological development of small molecule therapeutics; industrial analysis and industrial research services in the fields of small molecule therapeutics; design and development of computer hardware and software; design and development of small molecule therapeutics hardware; design and development of computer software for use with small molecule therapeutics hardware; clinical research in the fields of small molecule therapeutics; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies, immuno-oncology, inflammation, hematology and infectious disease; Medical and scientific research, namely, conducting clinical trials for others; conducting clinical trials for pharmaceutical products for others; scientific screening and assaying of therapeutics for medical purposes; chemical analysis; chemical research; biotechnology research; consultancy relating to biotechnology; consultancy services relating to research and development in the field of therapeutics

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 20, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
May 20, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 1, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 1, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 26, 2025 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 11, 2025 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 11, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 10, 2025 XAEC
ASSIGNED TO LIE
Mar 10, 2025 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 7, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 7, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 7, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 7, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 7, 2025 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 10, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 10, 2025 GNSL
SUSPENSION LETTER WRITTEN
Feb 10, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 27, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 27, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 27, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 7, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 7, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 7, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 25, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 9, 2024 NWOS
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jun 17, 2024 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Jun 17, 2024 PARI
NEW APPLICATION ENTERED
Mar 17, 2024 NWAP